MedTrace Logo

Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF)

NCT05406505 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2023-08-04

No results posted yet for this study

Summary

Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), increases natriuresis alone and synergistically when combined with loop diuretics in patients with AHF without increasing renin angiotensin- aldosterone activity. Thus, adding SGLT2i to the standard loop diuretic therapy might confer additional decongestive and natriuretic benefits while avoiding the adverse electrolyte abnormalities and neurohormonal activation associated with other diuretic combination. These potential benefits may help with improved clinical outcomes, but clinical evidence is still lacking.

Conditions

  • Acute Heart Failure

Interventions

DRUG

Dapagliflozin 10mg Tab

patients will receive once daily dapagliflozin 10 mg orally in addition to standard care

OTHER

Placebo

patients will receive placebo and standard care.

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Noha Mansour, PhD · Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, University of Mansoura

  • Moheb Magdy Mouris, MD · Department of Cardiology, Faculty of Medicine, University of Mansoura

  • Mohamed El-Husseiny Shams, Proffesor · Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, University of Mansoura

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-25
Primary Completion
2023-05-01
Completion
2023-07-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05406505 on ClinicalTrials.gov